The FDA Said No. Twice. Now Replimune Is Fighting for Survival.
The FDA rejected Replimune's melanoma drug for the second time, triggering layoffs, a 75% stock crash, and a public war of words with the agency. The fallout raises uncomfortable questions about whether oncolytic virus therapies can ever clear the regulatory bar.
Imagine spending years building a rocket, launching it, watching it explode, rebuilding it with better parts, launching it again, and watching it explode in the exact same way. That's roughly what just happened to Replimune.
On April 10, 2026, the FDA rejected Replimune's melanoma drug RP1 (vusolimogene oderparepvec) for the second time. The company responded by cutting 63 jobs, scaling back U.S. manufacturing, and publicly calling out the FDA for sending mixed signals. Its stock cratered 75% over five days.
This isn't just a bad week for one biotech. It's a warning sign for an entire class of cancer therapies.
A Drug That Actually Worked (on Paper)
Let's be clear about something: RP1's clinical data wasn't terrible. It was actually pretty compelling.
The drug is an oncolytic virus therapy, which is exactly what it sounds like. Scientists engineer a virus (in this case, a modified herpes simplex virus) to selectively infect and destroy cancer cells while leaving healthy tissue alone. Think of it as a biological smart bomb. RP1 was combined with nivolumab, a well-known checkpoint inhibitor, and tested in patients with advanced melanoma who had already failed other treatments.
In the IGNYTE Phase 2 trial of about 140 patients, the combo produced a roughly 33% response rate. For people whose cancer had already shrugged off prior immunotherapy, that's meaningful. Even more impressive: responses lasted a median of nearly 25 months. The safety profile was clean, with mostly mild, transient side effects. The FDA itself raised no safety concerns.
So why the rejection?
The FDA's Beef: Not What the Data Showed, but How It Was Collected
The core problem wasn't efficacy. It was trial design.
IGNYTE was a single-arm study, meaning every patient got the same treatment. There was no comparison group receiving a placebo or standard therapy. Single-arm trials are like taste-testing a new restaurant without ever eating anywhere else; you might love the food, but you can't definitively say it's than alternatives.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
better
The FDA said IGNYTE didn't qualify as an "adequate well-controlled study," which is regulatory speak for "we can't tell if this drug is actually responsible for what you're claiming." The agency also flagged patient heterogeneity, arguing the mix of patients in the trial made results hard to interpret. Were the responses driven by the drug, or by differences in the patient population?
Replimune pushed back hard. The company pointed out that 22 leading melanoma researchers signed an open letter after the first rejection in July 2025, arguing that the trial population reflected real-world clinical practice. At a September 2025 meeting, the FDA itself acknowledged that randomizing patients to receive only an anti-PD-1 drug (the standard approach) wasn't feasible.
And yet, when the second review came around, those same concerns resurfaced.
When the Ref Changes the Rules Mid-Game
This is where the story gets truly frustrating for Replimune.
After the first rejection in July 2025, the company did everything it was supposed to do. It resubmitted in October 2025 with new analyses addressing the FDA's concerns: mechanism of action data, comparisons with prior treatments, and additional context on patient heterogeneity. The FDA accepted the resubmission.
But according to Replimune, the review team refused to meet with the company despite repeated offers. A senior member of the original review team reportedly noted that the clinical reviewers had found adequate evidence of RP1's contribution to patient outcomes, but leadership disagreed.
CEO Sushil Patel called the decision "deeply disappointing" and accused the FDA of failing to exercise regulatory flexibility for a therapy addressing serious unmet need. He noted that approximately 8,500 Americans die from advanced melanoma each year.
The frustration isn't just about one drug. It's about a process that, from Replimune's perspective, kept moving the goalposts. The company says positions from the September 2025 meeting were contradicted in the April 2026 rejection letter. Pre-BLA meetings had seemingly endorsed the IGNYTE data as sufficient. Then, suddenly, it wasn't.
The Fallout: Jobs, Stock, and a Shrinking Company
The consequences were swift and brutal.
Replimune filed a WARN notice on April 13, disclosing that 63 employees in Woburn, Massachusetts would lose their jobs, primarily in manufacturing. The company signaled it would scale back its U.S. operations significantly. Shares plummeted, capping a five-day slide that erased three-quarters of the company's market value.
After the second rejection, Replimune indicated that RP1's development in advanced melanoma would be "non-viable" without an accelerated approval pathway. That prediction proved painfully accurate.
A Phase 3 confirmatory trial called IGNYTE-3 continues to enroll patients globally, but it feels like a life raft on a sinking ship. Without the revenue and momentum that an approval would have provided, funding that trial becomes exponentially harder.
Bigger Than Replimune: Is the Oncolytic Virus Dream Dying?
Zoom out, and the picture gets even bleaker for the field.
Only one oncolytic virus therapy has ever been approved by the FDA: Imlygic (T-VEC), way back in 2015 for melanoma lesions in skin and lymph nodes. That's it. One approval in over a decade, despite roughly 200 oncolytic virus products currently in clinical development.
The technology is elegant in theory. Viruses that selectively kill cancer cells and stimulate the immune system? It sounds like the plot of a sci-fi movie where humanity wins. But the regulatory path has proven brutally difficult. The FDA wants randomized, controlled data. Building those trials for oncolytic viruses, which are often injected directly into tumors and combined with other therapies, creates complex design challenges that don't map neatly onto traditional drug development frameworks.
Replimune's double rejection sends a chilling message to every company in this space: even with breakthrough therapy designation, priority review, strong response rates, and durable outcomes, you might still get turned away if your trial design doesn't check every box.
What Happens Next
Replimune isn't dead yet, but it's on life support. The IGNYTE-3 Phase 3 trial represents the company's last realistic shot at getting RP1 approved in the U.S. for melanoma. If that trial reads out positive results with a randomized design, the FDA's objections should evaporate. But Phase 3 trials take years and cost hundreds of millions of dollars, resources that a company with a 75% stock decline doesn't exactly have in abundance.
The broader question is whether the FDA and the biotech industry can find common ground on how to evaluate these novel therapies. Oncolytic viruses don't behave like traditional drugs. They're living, replicating biological agents that interact with the immune system in complex ways. Maybe the regulatory framework needs to evolve to match.
For now, though, Replimune's story serves as a cautionary tale: in biotech, good data isn't always enough. You also need the right trial design, the right regulatory relationship, and, apparently, the right review team.
Clinical & Regulatory4 min read
The Obesity Pill That Just Changed the Game
Eli Lilly's oral obesity pill Foundayo racked up nearly 1,400 prescriptions before it even hit pharmacy shelves nationwide. The real question: can a less potent pill outsell the needles by being the one patients actually take?
